Table 2.

Phase-III trials regarding targeted therapies in advanced gastric cancer

Ref.	Study/setting	Treatment	No. of patients	Response rate	Median PFS/TTP and OS (mo)
Anti-HER2 agents
Bang et al[8]	ToGA/first-line	Trastuzumab + CX/CF vs CX/CF	584	47% vs 35%	PFS, 6.7 vs 5.5; OS, 13.8 vs 11.1
Bang et al[47]	TyTAN/second-line	Lapatinib + P vs P	430	NA	PFS, 5.4 vs 4.4; OS, 11.0 vs 8.9
Hecht et al[48]	TRIO-013/LOGiC/first-line	Lapatinib + CAPOX vs CAPOX	545	53% vs 40%	PFS, 6.0 vs 5.4; OS, 12.2 vs 10.5
Anti EGFR1 agents
Lordick et al[55]	EXPAND/first-line	Cetuximab + CX vs CX	904	29% vs 30%	PFS, 4.4 vs 5.6; OS, 9.4 vs 10.7
Waddell et al[56]	REAL-3/first-line	Panitumumab + mEOX vs EOX	553	42% vs 46%	PFS, 6.0 vs 7.4; OS, 8.8 vs 11.3
Anti-VEGF agents
Ohtsu et al[64]	AVAGAST/first-line	Bevacizumab + CX vs placebo + CX	774	46% vs 37.4%	PFS, 6.7 vs 5.3; OS, 12.1 vs 10.1
mTOR inhibitors
Ohtsu et al[76]	GRANITE-1/first-line	Everolimus + BSC vs placebo + BSC	656	4.5% vs 2.1%	PFS, 1.7 vs 1.4; OS, 5.4 vs 4.3

HER2: Human epidermal growth factor receptor 2; EGFR1: Epidermal growth factor receptor 1; VEGF: Vascular endothelial growth factor; mTOR: Mammalian target of rapamycin; CX: Cisplatin and capecitabine; CF: Cisplatin and fluorouracil; P: Paclitaxel; CAPOX: Capecitabine and oxaliplatin; EOX: Epirubicin, oxaliplatin and capecitabine; mEOX: Modified EOX; BSC: Best supportive care; PFS: Progression-free survival; TTP: Time-to progression; OS: Overall survival; NA: Not applicable.